NN6 Stock Overview
NanoRepro AG develops, manufactures, and distributes rapid diagnostic tests and food supplements for home and professional use in Germany and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
NanoRepro AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.70 |
| 52 Week High | €2.78 |
| 52 Week Low | €1.55 |
| Beta | -3.06 |
| 1 Month Change | -7.36% |
| 3 Month Change | -15.84% |
| 1 Year Change | -22.02% |
| 3 Year Change | -83.33% |
| 5 Year Change | 46.55% |
| Change since IPO | -86.07% |
Recent News & Updates
Recent updates
Shareholder Returns
| NN6 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -7.6% | -5.1% | -1.5% |
| 1Y | -22.0% | -9.0% | 0.9% |
Return vs Industry: NN6 underperformed the German Medical Equipment industry which returned -6.2% over the past year.
Return vs Market: NN6 underperformed the German Market which returned -0.4% over the past year.
Price Volatility
| NN6 volatility | |
|---|---|
| NN6 Average Weekly Movement | 7.0% |
| Medical Equipment Industry Average Movement | 4.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: NN6 has not had significant price volatility in the past 3 months.
Volatility Over Time: NN6's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 17 | Lisa Jungst | www.nanorepro.com |
NanoRepro AG develops, manufactures, and distributes rapid diagnostic tests and food supplements for home and professional use in Germany and internationally. It provides products in the areas of family planning and disease detection, as well as food intolerances, allergies, and infectious diseases. The company offers rapid diagnostic tests, such as family planning, and preventive healthcare line products; tests for hospitals and medical practices to detect aids, Troponin I, D-dimer, streptococci antigen, influenza type A and B antigens, and microalbumin; and immunochromatographic lateral flow tests for the diagnostic detection of biomarkers, as well as SARS-CoV-2 antibody test and corona antigen rapid test.
NanoRepro AG Fundamentals Summary
| NN6 fundamental statistics | |
|---|---|
| Market cap | €22.21m |
| Earnings (TTM) | -€6.58m |
| Revenue (TTM) | €14.24m |
1.6x
P/S Ratio-3.4x
P/E RatioIs NN6 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NN6 income statement (TTM) | |
|---|---|
| Revenue | €14.24m |
| Cost of Revenue | €9.72m |
| Gross Profit | €4.52m |
| Other Expenses | €11.10m |
| Earnings | -€6.58m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.51 |
| Gross Margin | 31.76% |
| Net Profit Margin | -46.21% |
| Debt/Equity Ratio | 0% |
How did NN6 perform over the long term?
See historical performance and comparison